Abstract 312TiP
Background
High-grade gliomas (HGG) have a poor prognosis despite improvements using a multimodal approach. The progressive decline in neurological function and quality of life can have a devastating impact on patients, and caregivers. Palliative Care (PC) follow-up has proven benefits in terms of quality of life and cost savings for health care services. Guidelines recommend integrating PC as early as possible in the cancer management plan. However it’s often done at a later stage of disease progression.
Trial design
MATERIALS AND METHODS: Prospective, unblinded, randomized, controlled study, assigning eligible patients according to a 1:1 distribution without stratification, in control and intervention arms. TARGET POPULATION: Patients with an initial diagnosis of HGG, referred to a Medical Oncology consultation. PRIMARY ENDPOINTS Quality of life and symptom burden. SECONDARY ENDPOINT Overall survival, number and time of hospitalizations, number of visits to the ER. RECRUITING TIME: 6 months (March-August 2022). FOLLOW-UP: 2 years INTERVENTION: After referral by multidisciplinary meeting, at the first Medical Oncology consultation, a proposal for integration in the project will be made and informed consents will be obtained. Patients included will be distributed in a 1:1 ratio between the control arm (CA) (standard of care at the institution) and the intervention arm (IA) (standard of care + early follow-up in PC consultation). The QLQ-C30 and FACT-L questionnaires will be applied and clinical and socio-demographic data will be collected. Patients in the IA will be called for PC consultation within 2 weeks. The frequency of PC follow-up will be individualized. In both arms, questionnaires and updated clinical data will be collected at baseline, one month later, and then every 2 months in the first year and every 4 months in the second year.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.